JPRN-UMIN000032844招募中未知
Efficacy of Evolocumab in patients with arteriosclerosis obliterans. - Efficacy of Evolocumab in patients with arteriosclerosis obliterans.
Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui0 个研究点目标入组 20 人开始时间: 2018年6月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •-HMG-CoA reductase inhibitor is not used at the time of introduction -At the time of introduction of research drugs, patients with LDL-C less than 100 mg / dL -Contraindicated patients with HMG-CoA reductase inhibitors -Hypersensitivity to the study drug
研究者
相似试验
招募中
不适用
Efficacy of Alirocumab in the arteriosclerotic biomarker changes after percutaneous coronary angioplasty (PCI).coronary heart diseaseJPRN-UMIN000032843Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui50
已完成
不适用
Impact of lipid-lowering therapy with Evolocumab on coronary plaque regression in patients with coronary artery diseaseJPRN-UMIN000023448Chiba University Graduate School of Medicine3
已完成
不适用
Effects of Evolocumab on carotid plaque.carotid plaqueJPRN-UMIN000028178Iwate Medical University100
终止
不适用
Myocardial protective effect of evolocumab prior to coronary artery bypass graftingKCT0005577The Catholic University of Korea, Seoul St. Mary's Hospital100
招募中
不适用
The effect of evolocumab on myocardial infarct sizeDiseases of the circulatory systemKCT0005323BUCHEON SEJONG HOSPITA166